---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-048248"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2026-07-15T11:32:12+00:00"
generated_at: "2026-07-15T11:35:21.408235+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Senti Biosciences enters merger agreement with Celadon affiliate; stockholders to receive CVRs for SENTI-202 milestones

## Summary
- Celadon affiliate to acquire substantially all of Senti's business and pipeline via merger; Senti to remain public with streamlined structure.
- Stockholders will receive contingent value rights (CVRs) with potential payments up to $60M based on SENTI-202 BLA filing, FDA approval, and net sales milestones.
- Preliminary cash and cash equivalents of $6.5M as of June 30, 2026; combined with $6M additional funding from Celadon expected to fund operations through Q4 2026.
- Merger subject to stockholder approval and other conditions; expected to close in Q3 2026.
- Celadon, already largest stockholder with 54.6% ownership, could increase to up to 77.5% if additional notes are issued and exchanged.

## SEC filing metadata
- accession: 0001628280-26-048248
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2026-07-15T11:32:12+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 5.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000162828026048248/0001628280-26-048248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000162828026048248/snti-20260714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-048248
- JSON: https://secwatch.observer/filing/0001628280-26-048248.json
- Plain text: https://secwatch.observer/filing/0001628280-26-048248.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.